REGIS CORP (RGS)

US7589322061 - Common Stock

25.31  +1.69 (+7.15%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RGS. RGS was compared to 67 industry peers in the Diversified Consumer Services industry. While RGS is still in line with the averages on profitability rating, there are concerns on its financial health. RGS has a expensive valuation and it also scores bad on growth.



5

1. Profitability

1.1 Basic Checks

In the past year RGS was profitable.
RGS had a negative operating cash flow in the past year.
RGS had negative earnings in 4 of the past 5 years.
In the past 5 years RGS always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of 17.49%, RGS belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
RGS's Return On Equity of 157.83% is amongst the best of the industry. RGS outperforms 98.46% of its industry peers.
With a Return On Invested Capital value of 3.24%, RGS perfoms like the industry average, outperforming 58.46% of the companies in the same industry.
Industry RankSector Rank
ROA 17.49%
ROE 157.83%
ROIC 3.24%
ROA(3y)1.6%
ROA(5y)-3.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin of RGS (45.49%) is better than 98.46% of its industry peers.
RGS's Operating Margin of 8.56% is fine compared to the rest of the industry. RGS outperforms 63.08% of its industry peers.
In the last couple of years the Operating Margin of RGS has grown nicely.
The Gross Margin of RGS (99.96%) is better than 100.00% of its industry peers.
RGS's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 8.56%
PM (TTM) 45.49%
GM 99.96%
OM growth 3YN/A
OM growth 5Y92.69%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.74%
GM growth 5Y16.96%

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RGS is destroying value.
The number of shares outstanding for RGS remains at a similar level compared to 1 year ago.
RGS has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, RGS has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 0.35, we must say that RGS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.35, RGS is doing worse than 64.62% of the companies in the same industry.
A Debt/Equity ratio of 1.69 is on the high side and indicates that RGS has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.69, RGS is doing worse than 76.92% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF N/A
Altman-Z 0.35
ROIC/WACC0.27
WACC11.98%

2.3 Liquidity

RGS has a Current Ratio of 0.35. This is a bad value and indicates that RGS is not financially healthy enough and could expect problems in meeting its short term obligations.
RGS has a Current ratio of 0.35. This is amonst the worse of the industry: RGS underperforms 92.31% of its industry peers.
A Quick Ratio of 0.35 indicates that RGS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.35, RGS is doing worse than 89.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.35
Quick Ratio 0.35

2

3. Growth

3.1 Past

RGS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1642.82%, which is quite impressive.
RGS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 100.49% yearly.
Looking at the last year, RGS shows a very negative growth in Revenue. The Revenue has decreased by -12.97% in the last year.
RGS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -28.27% yearly.
EPS 1Y (TTM)1642.82%
EPS 3YN/A
EPS 5Y100.49%
EPS Q2Q%-171.22%
Revenue 1Y (TTM)-12.97%
Revenue growth 3Y-21%
Revenue growth 5Y-28.27%
Sales Q2Q%-13.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-107.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-6.39%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.68, the valuation of RGS can be described as very cheap.
RGS's Price/Earnings ratio is rather cheap when compared to the industry. RGS is cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.73, RGS is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for RGS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 0.68
Fwd PE N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, RGS is valued cheaper than 83.08% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.07

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.01
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

RGS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

REGIS CORP

NASDAQ:RGS (12/20/2024, 8:00:01 PM)

25.31

+1.69 (+7.15%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)01-29 2025-01-29
Inst Owners17.92%
Inst Owner Change286.38%
Ins Owners9.56%
Ins Owner Change0.88%
Market Cap57.71M
Analysts80
Price Target40.8 (61.2%)
Short Float %3.57%
Short Ratio1.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)-5.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.68
Fwd PE N/A
P/S 0.29
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB N/A
EV/EBITDA 7.07
EPS(TTM)37.35
EY147.57%
EPS(NY)-2.67
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS85.82
BVpS24.74
TBVpS-52.35
PEG (NY)N/A
PEG (5Y)0.01
Profitability
Industry RankSector Rank
ROA 17.49%
ROE 157.83%
ROCE 4.1%
ROIC 3.24%
ROICexc 3.29%
ROICexgc 5.85%
OM 8.56%
PM (TTM) 45.49%
GM 99.96%
FCFM N/A
ROA(3y)1.6%
ROA(5y)-3.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y22.11%
ROICexc growth 3YN/A
ROICexc growth 5Y42.42%
OM growth 3YN/A
OM growth 5Y92.69%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.74%
GM growth 5Y16.96%
F-Score5
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF N/A
Debt/EBITDA 4.71
Cap/Depr 6.63%
Cap/Sales 0.12%
Interest Coverage 0.97
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.35
Quick Ratio 0.35
Altman-Z 0.35
F-Score5
WACC11.98%
ROIC/WACC0.27
Cap/Depr(3y)33.16%
Cap/Depr(5y)56.96%
Cap/Sales(3y)0.77%
Cap/Sales(5y)2.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1642.82%
EPS 3YN/A
EPS 5Y100.49%
EPS Q2Q%-171.22%
EPS Next Y-107.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.97%
Revenue growth 3Y-21%
Revenue growth 5Y-28.27%
Sales Q2Q%-13.7%
Revenue Next Year-6.39%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.92%
EBIT growth 3YN/A
EBIT growth 5Y38.21%
EBIT Next Year66.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y97.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y98.22%
OCF growth 3YN/A
OCF growth 5YN/A